Astellas Pharma (ALPMF) Stock Forecast & Price Target

Compare

54 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ALPMF Analyst Ratings

Moderate Buy

1 Buy

1 Hold

0 Sell

Based on 2 analysts giving stock ratings to

Astellas

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ALPMF Stock 12 Month Forecast

Average Price Target

$12.34

▼(-9.00% Downside)

Based on 2 Wall Street analysts offering 12 month price targets for Astellas Pharma in the last 3 months. The average price target is $12.34 with a high forecast of $14.42 and a low forecast of $10.26. The average price target represents a -9.00% change from the last price of $13.56.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","15":"$15","9.75":"$9.75","11.5":"$11.5","13.25":"$13.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14.4225,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.42</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.34</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.256,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.26</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,9.75,11.5,13.25,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.38,12.537115384615385,12.694230769230769,12.851346153846155,13.008461538461539,13.165576923076923,13.322692307692307,13.479807692307693,13.636923076923077,13.794038461538461,13.951153846153845,14.108269230769231,14.265384615384615,{"y":14.4225,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.38,12.376923076923077,12.373846153846154,12.37076923076923,12.367692307692309,12.364615384615385,12.361538461538462,12.358461538461539,12.355384615384615,12.352307692307692,12.34923076923077,12.346153846153847,12.343076923076923,{"y":12.34,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.38,12.216615384615386,12.05323076923077,11.889846153846154,11.726461538461539,11.563076923076924,11.399692307692309,11.236307692307692,11.072923076923077,10.909538461538462,10.746153846153847,10.58276923076923,10.419384615384615,{"y":10.256,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.1,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.39,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.28,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.48,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.62,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.72,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.41,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.86,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.89,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.95,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.66,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.38,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$14.42

Average Price Target$12.34

Lowest Price Target$10.26

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

$12.82→$14.42

Buy

6.36%

Upside

Reiterated

12/17/25

Astellas Pharma (ALPMF) Gets a Buy from Goldman Sachs

Miki Sogi

Bernstein

$10.26

Hold

-24.37%

Downside

Reiterated

10/10/25

Bernstein Reaffirms Their Hold Rating on Astellas Pharma (ALPMF)

Seiji Wakao

J.P. Morgan

$10.9→$12.18

Hold

-10.18%

Downside

Reiterated

09/04/25

J.P. Morgan Sticks to Its Hold Rating for Astellas Pharma (ALPMF)JPMorgan analyst Seiji Wakao raised the price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY) to JPY1,900.00 (from JPY1,700.00) while maintaining a Neutral rating.

Shinichiro Muraoka

Morgan Stanley

$9.62

Hold

-29.09%

Downside

Reiterated

05/30/25

Morgan Stanley Sticks to Its Hold Rating for Astellas Pharma (ALPMF)

Hidemaru Yamaguchi

Citi

$15.38→$14.1

Buy

4.00%

Upside

Reiterated

05/01/25

Astellas Pharma Inc (4503:JP) (ALPMY) PT Lowered to JPY2,200 at CitiCiti analyst Hidemaru Yamaguchi lowered the price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY) to JPY2,200.00 (from JPY2,400.00) while maintaining a Buy rating.

Stephen Barker

Jefferies

$9.62

Hold

-29.09%

Downside

Reiterated

04/24/25

Analysts Offer Insights on Healthcare Companies: Astellas Pharma (Other OTC: ALPMF), Penumbra (NYSE: PEN) and Genmab (NASDAQ: GMAB)

Tony Ren

Macquarie

$14.1→$12.82

Buy

-5.46%

Downside

Reiterated

02/11/25

Astellas Pharma Inc (4503:JP) (ALPMY) PT Lowered to JPY2,000 at MacquarieMacquarie analyst Tony Ren lowered the price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY) to JPY2,000.00 (from JPY2,200.00) while maintaining a Outperform rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

$12.82→$14.42

Buy

6.36%

Upside

Reiterated

12/17/25

Astellas Pharma (ALPMF) Gets a Buy from Goldman Sachs

Miki Sogi

Bernstein

$10.26

Hold

-24.37%

Downside

Reiterated

10/10/25

Bernstein Reaffirms Their Hold Rating on Astellas Pharma (ALPMF)

Seiji Wakao

J.P. Morgan

$10.9→$12.18

Hold

-10.18%

Downside

Reiterated

09/04/25

Shinichiro Muraoka

Morgan Stanley

$9.62

Hold

-29.09%

Downside

Reiterated

05/30/25

Morgan Stanley Sticks to Its Hold Rating for Astellas Pharma (ALPMF)

Hidemaru Yamaguchi

Citi

$15.38→$14.1

Buy

4.00%

Upside

Reiterated

05/01/25

Stephen Barker

Jefferies

$9.62

Hold

-29.09%

Downside

Reiterated

04/24/25

Analysts Offer Insights on Healthcare Companies: Astellas Pharma (Other OTC: ALPMF), Penumbra (NYSE: PEN) and Genmab (NASDAQ: GMAB)

Tony Ren

Macquarie

$14.1→$12.82

Buy

-5.46%

Downside

Reiterated

02/11/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Astellas Pharma

1 Month

xxx

Success Rate

1/2 ratings generated profit

Average Return

-2.90%

reiterated a xxx

rating 11 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -2.90% per trade.

3 Months

xxx

Success Rate

1/1 ratings generated profit

Average Return

+1.50%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +1.50% per trade.

1 Year

Hidemaru YamaguchiCiti

Success Rate

1/1 ratings generated profit

Average Return

+33.70%

reiterated a buy rating 8 months ago

Copying Hidemaru Yamaguchi's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +33.70% per trade.

2 Years

xxx

Success Rate

1/1 ratings generated profit

Average Return

+33.70%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +33.70% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALPMF Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ALPMF has received 3 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. ALPMF average Analyst price target in the past 3 months is 12.34.

Each month's total comprises the sum of three months' worth of ratings.

ALPMF Financial Forecast

ALPMF Earnings Forecast

Next quarter’s earnings estimate for ALPMF is $0.28 with a range of $0.25 to $0.31. The previous quarter’s EPS was $0.29. ALPMF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ALPMF has Performed in-line its overall industry.

ALPMF Sales Forecast

Next quarter’s sales forecast for ALPMF is $3.37B with a range of $3.14B to $3.56B. The previous quarter’s sales results were $3.39B. ALPMF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ALPMF has Performed in-line its overall industry.

ALPMF Stock Forecast FAQ

What is ALPMF’s average 12-month price target, according to analysts?

Based on analyst ratings, Astellas Pharma Inc’s 12-month average price target is 12.34.

What is ALPMF’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for ALPMF, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ALPMF a Buy, Sell or Hold?

Astellas Pharma Inc has a consensus rating of Moderate Buy which is based on 1 buy ratings, 1 hold ratings and 0 sell ratings.

What is Astellas Pharma Inc’s price target?

The average price target for Astellas Pharma Inc is 12.34. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $14.42 ,the lowest forecast is $10.26. The average price target represents -9.00% Decrease from the current price of $13.56.

What do analysts say about Astellas Pharma Inc?

Astellas Pharma Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.

How can I buy shares of ALPMF?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Astellas Pharma (ALPMF) Stock Forecast & Price Target

ALPMF Analyst Ratings

ALPMF Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Astellas Pharma

ALPMF Analyst Recommendation Trends

ALPMF Financial Forecast

ALPMF Earnings Forecast

ALPMF Sales Forecast

ALPMF Stock Forecast FAQ

Detailed List of Analyst Forecasts